Compare Natera Inc. Common Stock (NTRA) vs YieldMax NVDA Option Income Strategy ETF (NVDY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs YieldMax NVDA Option Income Strategy ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while YieldMax NVDA Option Income Strategy ETF trades at $11.97 (market cap $1.39B). The key difference: Natera Inc. Common Stock is far larger — about 41× YieldMax NVDA Option Income Strategy ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, YieldMax NVDA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and YieldMax NVDA Option Income Strategy ETF for 44 Days on average.
| NTRA | NVDY | |
|---|---|---|
Market Cap | $57.03B | $1.39B |
Volume | 1,131,157 | 1,855,603 |
Sector | Health | Income / Options Overlay |
52-Week High | $425.64 | $17.21 |
52-Week Low | $179.42 | $11.58 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NVDY, the YieldMax NVDA Option Income Strategy ETF, trades at $12.54, up 0.88% on the day. The technical outlook is bearish, with moving averages signaling strong selling pressure, though oscillators are neutral. The fund generates weekly dividends but faces structural limitations on upside participation. Recent news highlights concerns over net asset value erosion despite high distribution yields.
The outlook is cautious; while NVDY offers high income, its strategy caps gains during NVIDIA rallies and may underperform in low-volatility environments. Key risks include NAV decay and reduced option income potential. Investors seeking pure NVIDIA exposure may find direct ownership more attractive for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About YieldMax NVDA Option Income Strategy ETF
NVDY is an actively managed ETF that pursues a synthetic covered call strategy on NVIDIA Corporation (NVDA) stock. The fund primarily sells call options on NVDA and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the high-growth potential of NVDA while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on NVDY →
